Sleep Apnea and GLP-1s: The SURMOUNT-OSA Data Men Need to See

Men are 2–3x more likely to have obstructive sleep apnea than women. Tirzepatide just became the first medication to significantly reduce OSA severity without surgery or a CPAP machine.

If you snore like a chainsaw, wake up exhausted, or your partner has banished you to the spare bedroom — there's a good chance obstructive sleep apnea (OSA) is involved. An estimated 30 million American men have it. Most are undiagnosed. And it's doing more damage than ruining your sleep: untreated OSA increases risk of heart attack, stroke, type 2 diabetes, depression, and erectile dysfunction.

The standard treatment — a CPAP machine — works. But compliance rates are brutal. Studies show that 30–50% of men prescribed CPAP abandon it within the first year. It's uncomfortable, it's unsexy, and it requires nightly discipline. That's why the SURMOUNT-OSA trial results matter: tirzepatide reduced OSA severity by up to 63%, and nearly half of participants on the higher dose achieved complete resolution of their sleep apnea.

The SURMOUNT-OSA Trial: What Happened

The SURMOUNT-OSA program consisted of two parallel Phase 3 trials studying tirzepatide (10mg and 15mg) in adults with moderate-to-severe obstructive sleep apnea and obesity. The primary endpoint was change in the apnea-hypopnea index (AHI) — the standard measure of sleep apnea severity, counting the number of breathing interruptions per hour of sleep.

Normal AHI is fewer than 5 events per hour. Moderate OSA is 15–30 events/hour. Severe is above 30. Trial participants started with a mean AHI of roughly 50 — deep in severe territory. After 52 weeks on tirzepatide, the average dropped to roughly 19 (moderate range), with many patients falling below the moderate threshold entirely.

In the non-CPAP arm (patients who weren't already using CPAP), approximately 43% of patients on tirzepatide 15mg achieved AHI below 5 — effectively resolving their sleep apnea. In the CPAP arm, tirzepatide worked as an adjunct, further reducing residual events that CPAP alone didn't eliminate.

Why This Matters Specifically for Men

OSA disproportionately affects men

Men are 2–3x more likely to develop obstructive sleep apnea than premenopausal women. Male anatomy (larger neck circumference, different fat distribution patterns) and the tendency to store visceral fat around the neck and upper airway make men structurally vulnerable. Obesity amplifies this — and visceral belly fat is exactly what GLP-1 medications target most effectively.

OSA tanks testosterone

Sleep fragmentation from OSA disrupts the nocturnal testosterone production cycle. Testosterone peaks during deep sleep phases. When OSA fragments sleep architecture — breaking deep sleep into short, shallow intervals — testosterone production suffers. Studies show men with untreated severe OSA have 10–15% lower testosterone levels on average. Treating the OSA can restore testosterone production without TRT.

OSA causes erectile dysfunction

The intermittent hypoxia (oxygen drops) caused by sleep apnea damages endothelial function — the ability of blood vessels to dilate properly. This is the same vascular mechanism that underlies erectile dysfunction. Treating OSA has been shown to improve erectile function in multiple studies, independent of weight loss.

The Weight Loss Connection

The SURMOUNT-OSA results aren't just a pharmacological effect — they're driven substantially by weight loss. Participants on tirzepatide lost an average of 18–20% of body weight over 52 weeks. Weight loss reduces fat deposits around the upper airway, decreases neck circumference, and reduces the mechanical compression that causes airway obstruction during sleep.

This is consistent with older research showing that a 10% reduction in body weight produces approximately a 26% reduction in AHI. The SURMOUNT-OSA results exceed this proportional effect, suggesting tirzepatide may have additional anti-inflammatory or direct airway benefits beyond weight loss — though this hasn't been conclusively established.

Does This Replace CPAP?

Not yet, and not for everyone. CPAP remains the first-line treatment for moderate-to-severe OSA. The SURMOUNT-OSA results are promising, but 52 weeks of data is not enough to establish long-term cardiovascular outcomes. CPAP's benefits for reducing stroke and heart attack risk are supported by decades of data.

That said, for men who can't tolerate CPAP (and there are millions), tirzepatide represents the first pharmacological alternative with clinically meaningful efficacy. The FDA granted Zepbound an expanded indication for OSA based on this data — making it the first medication approved specifically for treating obstructive sleep apnea.

What to Do If You Suspect Sleep Apnea

Get a sleep study. A home sleep test or in-lab polysomnography will measure your AHI and determine severity. You can request this through your primary care doctor or a sleep medicine specialist.

Know your risk factors. BMI over 30, neck circumference over 17 inches, loud snoring with witnessed breathing pauses, excessive daytime sleepiness, and morning headaches are the classic indicators.

Talk to your provider about GLP-1 medication. If you have obesity and moderate-to-severe OSA, tirzepatide now has an FDA indication for this exact combination. If you're already on semaglutide for weight loss, the weight reduction itself will likely improve your sleep apnea — though tirzepatide showed the strongest OSA-specific data.

GLP-1 Providers